%0 Journal Article
%T Hepatitis B antibody titers in Indonesian adolescents who received the primary hepatitis B vaccine during infancy
%A Hartono Gunardi
%A Adra Firmansyah
%A Sri Rezeki S Harun
%A Sudigdo Sastroasmoro
%J Paediatrica Indonesiana
%D 2013
%I Indonesian Pediatric Society
%X Background Hepatitis B (HB) has been classified as moderate-to-highly endemic in Indonesia. HB vaccination, the most effective method to prevent HB viral transmission, induces protective antibodies against HB surface antigen (anti-HBs). However, these antibodies decline in titer over time. Studies on the duration of protection and the prevalence of non-responders in Indonesian adolescents have been limited.Objectives To determine anti-HBs titers in 15-17-year old Indonesian adolescents given primary HB vaccine during infancy and the prevalence of non-responders after a HB vaccine booster dosage.Methods This cross-sectional study was performed from February to September 2008 on adolescents aged 15-17 years in three senior high schools in Jakarta who received complete primary HB vaccines during infancy, based on parents¡¯ recall. Investigations included HB vaccination history, anthropometric measurements, and blood tests for anti-HBs before and 4-6 weeks after a booster dose of HB vaccine.Results Of 94 subjects, 35 had protective anti-HBs and 59 had undetectable anti-HBs. A booster dose was administered to 58 of the non-protected subjects, of which 33 showed anamnestic responses. However, 25 subjects failed to generate protective anti-HBs. Taking into consideration the adolescents with protective anti-HBs before and after the booster dose, serologic protection was demonstrated in 73%. Non-responder prevalence was 27%. The high prevalence of non-responders may indicate bias of parents¡¯ recall.Conclusion Protective anti-HBbs is detected in less than half of Indonesian adolescents given primary HB vaccine during infancy. Following booster dosage, anamnestic responses are noted in one-third of subjects. The prevalence of non-responders is 27%, but confirmation with further study is needed.
%K adolescent
%K anti-HBs
%K booster
%K hepatitis B vaccine
%K immunity
%U http://www.paediatricaindonesiana.org/pdffile/53-3-7.pdf